Israel Secondary Fund (ISF)
Israel Secondary Fund (ISF) is a company that specializes in acquiring interests in Israel-related funds and private companies from various stakeholders such as investors, founders, and employees. With a history dating back to the inception of the secondary market in Israel in 1998, ISF's partners have been involved in numerous transactions within the Venture Capital and Private Equity community. They offer tailored solutions for Limited Partners positions, Secondary Direct acquisitions, and Structured Secondaries, providing additional capital and risk reduction options for funds and investors. ISF prides itself on its creative, discreet, and straightforward approach, prioritizing long-term partnerships and growth opportunities in collaboration with a wide range of PE and VC funds in Israel and internationally. Their investment professionals bring extensive experience in secondary transactions and venture capital, forming close relationships with key industry players to deliver value to all stakeholders involved.
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
Eyeview
Venture Round in 2018
Eyeview Inc. is a video advertising technology company based in New York that specializes in providing brands with effective return on investment for their video advertising expenditures. The company’s flagship platform, VideoIQ, integrates consumer, brand, and retail data to create personalized, one-to-one video advertisements, which can be delivered programmatically across various platforms, including television, desktop, tablet, and mobile devices. Eyeview also offers a range of solutions tailored to specific industries, such as lead generation for the automotive sector, in-store marketing for consumer packaged goods, and online booking for travel. The platform can be utilized through a managed service with support from Eyeview's team or via a self-service interface. Established in 2007, Eyeview has garnered recognition for its rapid growth and serves notable clients such as P&G, Walgreens, Lowes, Honda, and BMW.
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.